H O Smith

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. ncbi request reprint Changing trends in gestational trophoblastic disease
    Harriet O Smith
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 5286, USA
    J Reprod Med 51:777-84. 2006
  2. ncbi request reprint Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study
    H O Smith
    Department of Obstetrics and Gynecology, 1 University of New Mexico Health Sciences Center, MSC 10 5580, Albuquerque, NM 87131 5286, USA
    Int J Gynecol Cancer 16:298-305. 2006
  3. ncbi request reprint Gestational trophoblastic disease epidemiology and trends
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Science Center, Albuquerque, New Mexico, USA
    Clin Obstet Gynecol 46:541-56. 2003
  4. ncbi request reprint Gestational trophoblastic neoplasia in American Indians
    Harriet O Smith
    New Mexico Tumor Registry, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque 87131 5286, USA
    J Reprod Med 49:535-44. 2004
  5. ncbi request reprint Incidence and survival rates for female malignant germ cell tumors
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131 5286, USA
    Obstet Gynecol 107:1075-85. 2006
  6. ncbi request reprint Ethnic differences at risk for gestational trophoblastic disease in New Mexico: A 25-year population-based study
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque 87131, USA
    Am J Obstet Gynecol 188:357-66. 2003
  7. ncbi request reprint GPR30: a novel indicator of poor survival for endometrial carcinoma
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
    Am J Obstet Gynecol 196:386.e1-9; discussion 386.e9-11. 2007
  8. ncbi request reprint Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix?
    Harriet O Smith
    Department of Obstetrics and Gynecology, Health Sciences Center, University of New Mexico, 2211 Lomas Boulevard NE, Albuquerque, NM 87131, USA
    Gynecol Oncol 85:229-41. 2002
  9. ncbi request reprint Choriocarcinoma and gestational trophoblastic disease
    Harriet O Smith
    University of New Mexico Health Sciences Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 2211 Lomas Boulevard NE, Albuquerque, NM 87131 5286, USA
    Obstet Gynecol Clin North Am 32:661-84. 2005
  10. ncbi request reprint Trends in gestational choriocarcinoma: a 27-year perspective
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131 5286, USA
    Obstet Gynecol 102:978-87. 2003

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Changing trends in gestational trophoblastic disease
    Harriet O Smith
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 5286, USA
    J Reprod Med 51:777-84. 2006
    ..The New Mexico Tumor Registry (NMTR) and Surveillance, Epidemiology and End Results (SEER) registries were utilized to determine (30+)-year trends in gestational trophoblastic disease and choriocarcinoma...
  2. ncbi request reprint Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study
    H O Smith
    Department of Obstetrics and Gynecology, 1 University of New Mexico Health Sciences Center, MSC 10 5580, Albuquerque, NM 87131 5286, USA
    Int J Gynecol Cancer 16:298-305. 2006
    ..Prior use of radiosensitizing chemotherapy impacted response and survival significantly and should be considered in future clinical trials...
  3. ncbi request reprint Gestational trophoblastic disease epidemiology and trends
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Science Center, Albuquerque, New Mexico, USA
    Clin Obstet Gynecol 46:541-56. 2003
  4. ncbi request reprint Gestational trophoblastic neoplasia in American Indians
    Harriet O Smith
    New Mexico Tumor Registry, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque 87131 5286, USA
    J Reprod Med 49:535-44. 2004
    ..To analyze gestational trophoblastic neoplasia (GTN) trends among American Indians (AI) using population-based data...
  5. ncbi request reprint Incidence and survival rates for female malignant germ cell tumors
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131 5286, USA
    Obstet Gynecol 107:1075-85. 2006
    ..To evaluate 30-year, population-based trends in incidence and survival rates for malignant germ cell tumors originating within the female genital tract...
  6. ncbi request reprint Ethnic differences at risk for gestational trophoblastic disease in New Mexico: A 25-year population-based study
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque 87131, USA
    Am J Obstet Gynecol 188:357-66. 2003
    ..The purpose of this study was to compare gestational trophoblastic disease incidence rates with the use of population-based data...
  7. ncbi request reprint GPR30: a novel indicator of poor survival for endometrial carcinoma
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
    Am J Obstet Gynecol 196:386.e1-9; discussion 386.e9-11. 2007
    ..This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma...
  8. ncbi request reprint Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix?
    Harriet O Smith
    Department of Obstetrics and Gynecology, Health Sciences Center, University of New Mexico, 2211 Lomas Boulevard NE, Albuquerque, NM 87131, USA
    Gynecol Oncol 85:229-41. 2002
    ..The goal of this study was to determine if International Federation of Obstetrics and Gynecology (FIGO) subdivision into IA1 versus IA2 is predictive of survival differences for early invasive adenocarcinoma...
  9. ncbi request reprint Choriocarcinoma and gestational trophoblastic disease
    Harriet O Smith
    University of New Mexico Health Sciences Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 2211 Lomas Boulevard NE, Albuquerque, NM 87131 5286, USA
    Obstet Gynecol Clin North Am 32:661-84. 2005
    ..The rates of GTN and choriocarcinoma are decreasing and survival has dramatically improved...
  10. ncbi request reprint Trends in gestational choriocarcinoma: a 27-year perspective
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131 5286, USA
    Obstet Gynecol 102:978-87. 2003
    ..To evaluate trends in incidence and survival rates for gestational choriocarcinoma with the use of population-based data...
  11. ncbi request reprint Population-based study of microinvasive adenocarcinoma of the uterine cervix
    J C Webb
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, USA
    Obstet Gynecol 97:701-6. 2001
    ..57%, and 4.50% for IA(2) disease. CONCLUSION: Prognosis is excellent for microinvasive adenocarcinoma of the uterine cervix. In 96 cases (31.9%), simple hysterectomy alone proved adequate...
  12. ncbi request reprint Absence of epidermal growth factor receptor mutations in cervical cancer
    H Arias-Pulido
    Department of Pathology, Division of Hematology Oncology, The University of New Mexico Cancer Center, Albuquerque, New Mexico
    Int J Gynecol Cancer 18:749-54. 2008
    ..Our results suggest, therefore, that treatment of CC patients with TKIs may not have the same efficacy as seen in patients with lung cancer, and that targeting the EGFR with other inhibitors may be more appropriate...
  13. ncbi request reprint Gestation trophoblastic diseases: management of cases with persistent low human chorionic gonadotropin results
    Laurence A Cole
    Division of Women s Health Research, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, 2211 Lomas Boulevard NE, Albuquerque, NM 87131 5286, USA
    Obstet Gynecol Clin North Am 32:615-26. 2005
    ..Three distinct sources are discussed for persistent low hCG results: quiescence gestational trophoblastic disease, false-positive hCG results, and pituitary hCG...
  14. ncbi request reprint Cervical neoplasia complicating pregnancy
    Carolyn Y Muller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, 1 University of New Mexico, MSC 10 5580, Albuquerque, NM 87131, USA
    Obstet Gynecol Clin North Am 32:533-46. 2005
    ..Novel fertility-sparing techniques for cervical cancer and their impact on complications of future pregnancies are also discussed...
  15. ncbi request reprint Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group
    Sidney A Scudder
    University of California Davis Medical Center, Sacramento, CA 95817, USA
    Gynecol Oncol 96:610-5. 2005
    ..To evaluate the toxicity of amifostine when used in combination with carboplatin and paclitaxel...
  16. ncbi request reprint Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group
    Harriet O Smith
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, USA
    Gynecol Oncol 84:140-4. 2002
    ..This study was conducted to determine the objective response of trimetrexate in patients with advanced or recurrent leiomyosarcoma of the uterus...
  17. ncbi request reprint Adenocarcinoma in situ of the cervix: sensitivity of detection by cervical smear: will cytologic screening for adenocarcinoma in situ reduce incidence rates for adenocarcinoma
    Harriet O Smith
    Cancer 96:319-22. 2002
  18. doi request reprint Estrogen signaling through the transmembrane G protein-coupled receptor GPR30
    Eric R Prossnitz
    Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Annu Rev Physiol 70:165-90. 2008
    ..In this review, we provide an overview of the evidence for the cellular and physiological actions of GPR30 in estrogen-dependent processes and discuss the relationship of GPR30 with classical estrogen receptors...
  19. ncbi request reprint Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial
    Maurie Markman
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 88:282-8. 2003
    ....
  20. ncbi request reprint Persistent low levels of human chorionic gonadotropin: A premalignant gestational trophoblastic disease
    Sarah A Khanlian
    USA hCG Reference Service, Division of Women s Health Research, Department of Obstetrics and Gynecology, University of New Mexico, 2211 Lomas Boulevard NE, Albuquerque, NM 87131, USA
    Am J Obstet Gynecol 188:1254-9. 2003
    ..This study was undertaken to evaluate the significance of persistent low-level human chorionic gonadotropin (hCG) titers (usually <50 IU/L) in the absence of clinical evidence of pregnancy or gestational trophoblastic disease...
  21. ncbi request reprint TLK-286
    Claire F Verschraegen
    University of New Mexico, Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque 87131, USA
    IDrugs 7:771-81. 2004
    ..Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer...
  22. ncbi request reprint Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study
    Mace L Rothenberg
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Gynecol Oncol 95:506-12. 2004
    ....
  23. ncbi request reprint In vivo light scattering measurements for detection of precancerous conditions of the cervix
    Judith R Mourant
    Bioscience Division, Los Alamos National Laboratory, PO Box 1663, MS E535, Los Alamos, NM 87545, USA
    Gynecol Oncol 105:439-45. 2007
    ..To examine the utility of in vivo elastic light scattering measurements to diagnose high grade squamous interepithelial lesions (HSIL) of the cervix...
  24. ncbi request reprint Primary plasmacytoma arising in an endocervical polyp with detection of neoplastic cells on papanicolaou test. A case report and review of the literature
    Edgar G Fischer
    Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque 87131 5301, USA
    Arch Pathol Lab Med 127:e28-31. 2003
    ..The cytologic and histopathologic findings of plasmacytomas of the uterine cervix are discussed, including the utility of immunophenotypic and molecular techniques to confirm the neoplastic diagnosis...